TP53 and acute myeloid leukemia: In the present study, AFM28 demonstrated to specifically bind to CD16A (FcγRIIIA) and CD123, mediating the depletion of AML cell lines via ADCC irrespective of their levels of CD123, CD64 expression or mutational profile (e.g., TP53).